91AV

Phishing warning 01-May-2024
We are aware of phishing emails targeting speakers of events whose names appear on our events pages. If you are unsure if an email regarding event registration or accommodation has come from us please contact us and do not provide any credit card details or personal information

3rd new perspectives in DMPK: the impact of drug design

8 February 2016 12:00 - 9 February 2016 16:00, London, United Kingdom


Introduction
This meeting will provide a forum for the exchange of ideas between principal members of the DMPK research community. The agenda will include keynote talks from industry leaders, who will frame specific topic discussions with more global views of how DMPK can bring value to the process of informing drug discovery. The emphasis throughout will be on building dialogue between participants who will range from experienced project/laboratory leader to early-career researchers, via platform presentations, Q&A, poster sessions, and associated social mixer events. The programme will consist of invited oral contributions, short talk presentations and poster presentations. Who should attend? Medicinal chemists, drug discovery scientists, pharmacologists, toxicologists – from academia and industry. The Call for Papers is now open, and abstracts are invited for both posters. The closing date is 15th January.
Sponsorship and Exhibition Opportunities Contact the Secretariat for details of sponsorship opportunities, and there will be a limited number of exhibition stand spaces available. The conference dinner will be held on the evening of Monday, 8th February. This is an optional extra, charged at £50.
Speakers
  • Neil Berry University of Liverpool, United Kingdom
  • Marcel Hopp Genentech, United States
  • Owen Jones AstraZeneca, United Kingdom
  • Richard Weaver XenoGesis, United Kingdom
  • Thierry Lave Roche, Switzerland
  • Robert Glen Imperial College London and University of Cambridge, United Kingdom
  • Keynote: Charlotte Allerton Pfizer Worldwide R&D, United States
  • Scott Summerfield GlaxoSmithKline, United Kingdom
  • Rowan Stringer Novartis, Switzerland
  • Nicola Colclough AstraZeneca, United Kingdom
  • Philip MacFaul RedX Pharma, United Kingdom
  • Richard Schneider Pfizer, United States
  • Klaus Pors University of Bradford, United Kingdom

Venue
The 91AV

Library, The 91AV, Burlington House, Piccadilly, London, W1J 0BA, United Kingdom

Useful links

Committee
Organised by
Organised jointly by RSC Biological and Medicinal 91AV Sector BPS (British Pharmacological Society) DMG (Drug Metabolism Group) DMDG (Drug Metabolism Discussion Group)
Contact information
Search
 
 
Showing all upcoming events
Start Date
End Date
Location
Subject area
Event type

Advertisement
Spotlight


E-mail Enquiry
*
*
*
*